Fazirsiran: A Treatment for Alpha-1 Liver Disease

Fazirsiran is an RNA interference drug designed to stop liver cells from producing the misfolded protein that causes progressive liver damage in people with alpha-1 antitrypsin deficiency (AATD). In a phase 2 trial called SEQUOIA, it reduced the concentration of the toxic protein in the liver by about 93% compared to placebo and improved liver tissue on biopsy in every treated patient. The drug works at the genetic-instruction level, intercepting the messenger RNA that tells liver cells to make the harmful protein before it ever gets built. That approach makes it fundamentally different from anything previously available for alpha-1 liver disease, where the only definitive treatment has been organ transplantation.

Why the Liver Suffers in Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin (AAT) is a protein normally made in the liver and released into the bloodstream, where it protects the lungs from damage by enzymes produced during inflammation. In the most common severe form of the deficiency, known as the ZZ genotype, a single-letter change in the gene causes the protein to fold incorrectly. Instead of being secreted into the blood, the misshapen “Z-AAT” proteins stick together, forming clumps called polymers that get trapped inside liver cells.

These polymer accumulations build up in a cellular compartment called the endoplasmic reticulum and trigger chronic stress, inflammation, and scarring. When the liver’s cleanup systems can’t keep pace with the rate of production, inclusion bodies form and the damage escalates toward fibrosis, cirrhosis, and an increased risk of liver cancer.¹ Research in mouse models and human tissue has traced the molecular steps: the retained polymers activate stellate cells in the liver, which lay down collagen and other structural proteins that stiffen the tissue and progressively destroy its architecture.²

The critical point is that the liver damage in AATD is not caused by the absence of functional AAT. It is caused by the presence of the misfolded version piling up where it was made. That distinction is what makes fazirsiran’s strategy logical: if you stop the liver from producing the toxic protein altogether, you remove the source of the injury.

How Fazirsiran Silences the Problem Gene

Fazirsiran belongs to a class of drugs called small interfering RNAs (siRNAs). These are short, synthetic strands of RNA designed to bind to a specific messenger RNA sequence inside a cell and mark it for destruction. In fazirsiran’s case, the target is the messenger RNA that encodes Z-AAT. Once that message is degraded, the cell simply stops making the misfolded protein for a period of time.

Getting the drug into the right cells is half the challenge. Fazirsiran uses a sugar-based delivery tag called GalNAc, short for N-acetylgalactosamine. Liver cells are covered in receptors that recognize GalNAc and pull it inside, so attaching this tag to the siRNA essentially gives it a zip code for the liver.³ This targeted delivery means the drug concentrates in hepatocytes, the very cells producing the harmful protein, while largely sparing the rest of the body.⁴

One practical advantage of GalNAc-siRNA drugs is their dosing schedule. Because the silencing effect persists inside the cell for weeks after a single injection, fazirsiran is given subcutaneously, typically once a month or less frequently, rather than requiring daily pills. The chemical modifications built into the siRNA also help it resist degradation and avoid triggering immune sensors in the liver. Research has shown that specific modifications to the RNA backbone largely prevent the activation of Toll-like receptors in liver immune cells, which is important for keeping the treatment safe over repeated doses.⁵

What the SEQUOIA Trial Found

The clearest evidence for fazirsiran so far comes from the SEQUOIA phase 2 trial, a placebo-controlled study in adults with AATD-related liver disease. The results were striking: patients who received fazirsiran saw a median reduction in liver Z-AAT concentration of 93%, compared to a 26% increase in the placebo group. Every patient treated with fazirsiran showed a reduction in the globular protein inclusions visible on liver biopsy.⁶ The drug also produced dose-dependent drops in Z-AAT levels in the blood, ranging from roughly 61% to 94% depending on the dose, alongside improvements in liver tissue appearance and a generally favorable safety profile.⁷

These numbers are encouraging, but it is worth keeping some perspective. SEQUOIA was a phase 2 trial, meaning it was designed primarily to establish proof of concept, optimal dosing, and safety rather than to prove long-term clinical outcomes like prevention of cirrhosis or avoidance of transplant. The biopsy improvements are biologically meaningful, yet whether they translate into fewer patients progressing to end-stage liver disease will take years to confirm. Phase 3 trials are in progress, and expert panels have recommended that those larger studies enroll patients with moderate to advanced fibrosis to best measure whether the histological improvements lead to real clinical benefit.⁸

What Fazirsiran Does Not Address

AATD is a two-organ disease. The liver suffers because the misfolded protein accumulates inside it; the lungs suffer because too little functional AAT reaches the bloodstream to protect them. Fazirsiran tackles the liver side by shutting down production of the toxic Z-AAT, but that same shutdown means even less functional protein gets into circulation. The drug is not expected to help the lung component of the disease at all. If anything, by further reducing circulating AAT levels, it could theoretically worsen the lung’s vulnerability, though the clinical significance of that trade-off is still being evaluated.

For patients whose primary burden is emphysema or chronic obstructive pulmonary disease (COPD) caused by the deficiency, fazirsiran is not the answer. Those individuals typically receive augmentation therapy, weekly intravenous infusions of purified AAT protein from donor blood, to raise protective levels in the lungs. Fazirsiran fills a different gap entirely: the liver disease for which augmentation therapy does nothing.

Why a New Treatment Matters So Much

Before fazirsiran entered clinical testing, the only definitive treatment for alpha-1 liver disease was a liver transplant. Transplantation cures the liver problem and restores normal AAT production because the donor liver makes the healthy version of the protein. Survival outcomes after transplant are generally good. One study of ZZ patients found five-year survival rates around 80%, while another longer-term analysis reported cumulative survival of about 95% at five years and 89% at twenty years.⁹¹⁰

But transplantation is a last resort, not a scalable therapy. The organ shortage is real, the surgery is major, and recipients commit to lifelong immunosuppression with its own risks. Many patients with alpha-1 liver disease live for years with slowly worsening fibrosis, watching their liver function decline without any pharmacological option to slow the process. A drug that could halt or reverse fibrosis before transplant becomes necessary would change the entire trajectory of the disease. That is the space fazirsiran is trying to fill.

Not Everyone with the ZZ Genotype Gets Severe Liver Disease

One of the puzzling features of AATD is its unpredictability. All individuals with the ZZ genotype carry the same mutation in both copies of the gene, yet the liver disease varies enormously in timing and severity. Some people develop cirrhosis in childhood; others reach old age with minimal liver problems. Neonatal cholestasis, a form of liver inflammation in the first weeks of life, affects a subset of ZZ infants but resolves on its own in many of them. At the other end of the spectrum, some adults develop liver cancer without any prior diagnosis of AATD.¹¹

Researchers suspect that genetic modifiers, environmental exposures like alcohol or viral hepatitis, and differences in the liver’s protein-disposal machinery all contribute to who develops severe disease. But those cofactors have not been fully identified, and it remains impossible to predict at diagnosis which individuals will progress to serious liver damage. This uncertainty complicates clinical decisions about when to start treatment. A drug like fazirsiran would ideally be given early enough to prevent irreversible fibrosis, but if many ZZ patients never develop clinically significant liver disease, treating everyone from the point of diagnosis could mean treating a large number of people who would have done fine without it. Balancing early intervention against overtreatment will be a central question as fazirsiran moves toward potential approval.

Living with Alpha-1 Liver Disease

Beyond the medical metrics, the day-to-day burden of AATD liver disease is substantial and historically underappreciated. A qualitative study of patients found that the most prominent impacts fell on work and employment, leisure activities, and personal relationships. Limitations on mobility were also highly significant.¹² Fatigue, abdominal discomfort, and the anxiety of living with a progressive condition for which no medication existed all take a toll that standard clinical measurements tend to miss.

Part of the problem is that the tools used to measure quality of life in AATD have overwhelmingly focused on lung symptoms. A review of existing patient-reported outcome measures found that none of them assessed liver-related symptoms, other non-pulmonary complications, or concerns related to genetics and finances, all of which shape what patients actually experience.¹³ For fazirsiran trials to capture the full picture of benefit, regulators and researchers will need instruments that reflect the liver-specific burden. That gap is being recognized, but validated disease-specific tools are still in development.

Gene Editing and Other Approaches on the Horizon

Fazirsiran is the most clinically advanced liver-targeted therapy for AATD, but it is not the only strategy under investigation. Gene editing using CRISPR technology represents a fundamentally different angle: rather than repeatedly silencing the gene’s messenger RNA, CRISPR aims to permanently alter or disable the defective gene in liver cells. In mouse models carrying the human Z-AAT gene, CRISPR delivered via viral vectors reduced liver protein aggregates by more than 98% after a single treatment.¹⁴ A separate study using a similar approach not only reversed the liver scarring and inflammation associated with Z-AAT accumulation but also confirmed significant disruption of the disease-causing gene at the DNA level.¹⁵

A more ambitious version of CRISPR editing doesn’t just knock out the bad gene but tries to correct the mutation back to the healthy sequence. One group co-injected two viral vectors, one carrying the CRISPR machinery and another carrying a repair template, and achieved partial restoration of functional “M-AAT” protein in the blood of treated mice.¹⁶ If perfected, this dual approach could theoretically address both the liver and lung sides of the disease in one treatment: stopping the toxic buildup and simultaneously producing the protective protein the body needs. That possibility remains years away from human testing, but it illustrates why researchers are pursuing multiple strategies in parallel rather than betting everything on a single mechanism.

The contrast between fazirsiran and gene editing highlights an important trade-off. Fazirsiran requires ongoing injections for as long as the patient needs protection; stopping the drug presumably allows Z-AAT production to resume. Gene editing, if it works and proves safe, could be a one-time fix. But gene editing in humans carries risks that siRNA approaches do not, including off-target DNA cuts and the challenges of delivering editing machinery efficiently to enough liver cells. For now, fazirsiran’s approach of manageable, reversible gene silencing is the one closest to reaching patients.

Ongoing Uncertainties Around Long-Term Use

Several open questions will shape whether fazirsiran becomes a standard treatment. The most pressing is durability of benefit: while clearing toxic protein from the liver over a year or two is promising, AATD is a lifelong condition. Whether sustained Z-AAT suppression over decades actually prevents cirrhosis, reduces the need for transplant, or lowers the risk of liver cancer requires data that doesn’t exist yet. Phase 3 results, expected in the coming years, should begin to fill that gap.

There are also practical questions about who should receive the drug and when. Patients with early fibrosis might benefit most from preventing progression, but enrolling them in trials and proving benefit is difficult because many would progress slowly or not at all even without treatment. Patients with advanced cirrhosis might benefit from halting further damage, but whether a heavily scarred liver can meaningfully recover once Z-AAT production stops is less clear. Expert guidance has suggested enrolling patients with moderate to advanced fibrosis in phase 3 trials as the group most likely to show measurable change within a trial’s timeframe.⁸

The lung question also lingers. Since fazirsiran reduces circulating AAT, patients receiving the drug who also have lung involvement might need concurrent augmentation therapy to maintain pulmonary protection. Managing a two-organ disease with two separate treatments, each addressing one organ while being neutral or counterproductive to the other, is clinically awkward. How physicians coordinate these therapies in practice will depend on individual patient profiles: someone with advanced liver fibrosis but stable lungs faces a very different calculation than someone with mild liver disease but progressive emphysema.

Finally, cost and access are likely to shape real-world impact. GalNAc-siRNA therapeutics that have already reached the market for other liver conditions carry price tags in the tens of thousands of dollars per year. For a disease as rare as AATD, insurance coverage and global availability could determine whether fazirsiran reaches the patients who need it most or remains limited to those in well-resourced health systems. These questions sit outside the lab, but for a community that has waited decades for a liver-targeted therapy, they matter just as much as the biology.